Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
7
×
san diego top stories
san francisco blog main
7
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
amgen
bristol-myers squibb
cancer
eli lilly
fda
fremanezumab
merck
novartis
teva pharmaceutical
alder biopharmaceuticals
allergan
calcitonin gene-related peptide
What
drug
7
×
new
7
×
approval
fda
approved
bio
class
companies
drugs
known
medicine
migraine
nash
roundup
won
advantages
amgen
arguments
bar
big
biogen’s
biopharmaceutical
brings
cancer
candidates
cholesterol
commercialized
competitors
convo
data
decades
deeper
developed
disease
dna
earlier
expect
expensive
faces
failures
Language
unset
Current search:
new
×
drug
×
" boston blog main "
×
" san francisco blog main "
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines